Content intended for healthcare professionals. By continuing, you confirm you are a HCP.
Our solutions
Bone-health intelligence across two modalities
From the DXA suite to the X-ray reading room, our TBS® solutions add clinically meaningful bone insight to the imaging you already perform: No new scans, no new workflows.
The clinical need
Osteoporosis is a silent disease — until a bone breaks
~500M
people worldwide have osteoporosis1 and most go undetected2
30%
of high-risk patients present with normal or osteopenic BMD3
30-60%
of high-risk osteoporosis patients go untreated4
Our vision & mission
Creating an era where healthy bones are the norm
We help clinicians reveal more from routine imaging — every patient, every scan — for better care.
TBS · DXA
CE · FDA
The global standard in fracture-risk assessment. Bone microarchitecture assessment from routine DXA scans.
radiobotics · X-ray
CE
One of Europe's most deployed AI fracture-detection tools. Decision support for paediatric and adult patients.
TBS · DXA
CE · FDA pending
Turn existing images into opportunity. AI software that surfaces bone-fragility risk opportunistically from routine X-rays.
TBS · DXA
In development
Surgical planning deserves bone quality, not just bone density. Pre- and post-surgical bone assessment for orthopaedic planning.
The patient journey
Present at every stage of bone health
From the first opportunistic look to surgical planning, our solutions support clinicians across the patient journey. Each imaging touchpoint is a chance to check bone status.
Screen
Catch risk early
Reveal bone fragility from routine X-rays.
detect
Diagnose accurately
AI-powered, automatic detection of trauma-related findings.
Assess
Quantify fracture risk
Add bone microarchitecture to routine DXA for a complete risk picture.
Monitor
Track treatment
See treatment response over time — in months, not years.
Operate
Plan surgery
Assess site-specific bone quality before and after orthopaedic surgery.
The road ahead
Broader & deeper
Tools across the bone-health continuum
How to choose
Meet clinicians in the imaging they already do
Medimaps builds the imaging software that helps clinicians understand bone health, from the microarchitecture that determines whether bone will break to the fractures hiding in X-rays.
You run a DXA programme
TBS Osteo™ adds bone microarchitecture to every routine lumbar-spine DXA — no extra scan, no extra radiation.
You read X-rays in ED or radiology
RB Fracture™ flags fractures and trauma findings automatically; TBS Reveal™ surfaces bone fragility opportunistically.
You plan orthopaedic surgery
TBS Ortho™ (in development) is designed to assess site-specific bone quality before and after surgery.
Talk to our clinical team and we'll point you to the right solution for your setting.
TBS Osteo™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. TBS Osteo is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 2460). TBS Osteo is FDA 510(k) cleared (K243218) for use in the United States. TBS Osteo is included on the Australian Register of Therapeutic Goods (ARTG No. 528950) as "Inovanz Pty Ltd — X-ray system, diagnostic, general-purpose, application program software". Manufacturer: Medimaps Group SA, Chemin du Champ-des-Filles 36A, 1228 Plan-les-Ouates, Geneva, Switzerland. Always follow the instructions for use.
RBfracture™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. RBfracture is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 0123). RBfracture is included on the Australian Register of Therapeutic Goods (ARTG No. 484605) as “Emergo Asia Pacific Pty Ltd T/a Emergo Australia - X-ray image interpretive software”. Manufacturer: Radiobotics ApS, Esplanaden 8C, 1tv, 1263, Copenhagen, Denmark. Always follow the instructions for use.
TBS Reveal™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. TBS Reveal is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 2460). FDA clearance is pending; TBS Reveal is not available for clinical use in the United States. Manufacturer: Medimaps Group SA, Chemin du Champ-des-Filles 36A, 1228 Plan-les-Ouates, Geneva, Switzerland. Always follow the instructions for use.
TBS Ortho™ is currently under development and is not yet CE marked, FDA cleared, or otherwise registered for clinical use in any jurisdiction. It is not available for purchase or clinical use at this time.
References (4)
1. Kanis, J.A., McCloskey, E.V., Johansson, H., Oden, A., Melton, L.J. and Khaltaev, N. (2008). A reference standard for the description of osteoporosis. Bone, 42(3), pp.467–475. doi:10.1016/j.bone.2007.11.001.
2. Compston, J (2020). Reducing the treatment gap in osteoporosis. The Lancet Diabetes & Endocrinology, 8(1), pp.p7–9. doi:https://doi.org/10.1016/s2213-8587(19)30378-x.
3. Hans, D., Goertzen, A.L., Krieg, M.-A. and Leslie, W. D (2011). Bone Microarchitecture Assessed by TBS Predicts Osteoporotic Fractures Independent of Bone Density: The Manitoba Study. Journal of Bone and Mineral Research, 26(11), pp.2762–2769. doi:10.1002/jbmr.499.
3. Siris, E.S., Miller, P.D., Barrett-Connor, E., Faulkner, K.G., Wehren, L.E., Abbott, T.A., Berger, M.L., Santora, A.C. and Sherwood, L.M. (2001). Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women. JAMA, [online] 286(22), p.2815. doi:10.1001/jama.286.22.2815.
4. Kanis, J.A., Norton, N., Harvey, N.C., Jacobson, T., Johansson, H., Lorentzon, M., McCloskey, E.V., Willers, C. and Borgström, F. (2021). SCOPE 2021: A new scorecard for osteoporosis in Europe. Archives of Osteoporosis, 16(1). doi:10.1007/s11657-020-00871-9.